4 targeted drugs for treatment of the MET positive cancer

Date:2024-07-03 Views: 507 Times

MET, also known as the hepatocyte growth factor receptor (HGFR), is a protein that is involved in cellular growth, survival, and migration. In some cancers, the MET gene may become altered or amplified, leading to increased MET signaling and contributing to tumor growth and progression.

Several targeted therapies have been developed or are under investigation for the treatment of MET-positive cancers. Some of these drugs include:


Capmatinib is a selective MET inhibitor approved for the treatment of metastatic NSCLC with a MET exon 14 skipping mutation. It has demonstrated efficacy in clinical trials for this specific patient population.

Approval Statushttps://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capmatinib-metex14-mutated-metastatic-non-small-cell-lung-cancer
Instructions for use:dosing, indications, interactions...etc.https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213463s000lbl.pdf


Savolitinib is another selective MET inhibitor currently under investigation for the treatment of various MET-positive cancers, including NSCLC, renal cell carcinoma, and gastric cancer.

Approval Statushttps://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-savolitinib-metastatic-non-small-cell-lung-cancer-met-exon-14-skipping-mutation
Instructions for use:dosing, indications, interactions...etc.https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212398s000lbl.pdf


Tepotinib is a potent and selective MET inhibitor under investigation for the treatment of MET-positive tumors, including NSCLC and hepatocellular carcinoma.

Approval Statushttps://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-tepotinib-metastatic-non-small-cell-lung-cancer-met-exon-14-skipping-alterations
Instructions for use:dosing, indications, interactions...etc.https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213372s000lbl.pdf


Gumarontinib (code: SCC244) is an oral, potent and highly selective small molecule MET inhibitor. Gumarontinib has shown excellent pharmacokinetic characteristics, highly effective and durable efficacy and favorable safety profile in NSCLC patients with MET alterations. 

Approval Statusハイイータン® Gumarontinib (MET inhibitor) has been successfully approved in Japan
Approval Status in JapaneseMET阻害剤「ハイイータン® 錠50 mg」MET遺伝子エクソン14スキッピング変異陽性の切除不能な進行・再発の非小細胞肺癌に対する製造販売承認を取得


These are just a few examples of the targeted drugs that have been developed or are under investigation for the treatment of MET-positive cancers. It's important to note that the effectiveness of these drugs will depend on the specific tumor type, the presence of other genetic alterations, and individual patient factors.Always consult with a healthcare professional to discuss the most appropriate treatment options for your specific situation.